Geron Corporation

NASDAQ:GERN

Biotechnology

Healthcare
$0.91 +4.07%

+$0.05 today

Market cap
$588.19M
Beta
0.60
P/E (TTM)
-12.3
EPS (TTM)
-$0.10
52W Low $1.04High $2.01

Volume 19.64M

Average 16.28M

Returns on capital

Geron Corporation management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-38.0%

avg -54.2%

ROIC

-11.3%

avg -38.6%

ROA

-15.0%

avg -31.7%

Analysis

ROIC is currently the strongest return metric at -11.3% versus its period average of -38.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Joseph Emile Eid

Executive Vice President of Research & Development and Chief Medical OfficerUSD 1M59——

Michelle J. Robertson

Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting OfficerUSD 810.55K59——

Harout Semerjian

Chief Executive Officer, President & DirectorUSD 526.36K560<0.01%

Timothy Williams

Executive Vice President, Chief Legal Officer & Corporate SecretaryUSD 485.32K490<0.01%

Ahmed ElNawawi

Executive Vice President & Chief Commercial OfficerUSD 307.93K4510.00K<0.01%

Aron Feingold

Vice President of Investor Relations & Corporate Communications————

Shannon Odam

Executive Vice President & Chief People Officer—51——

Dawn Schottlandt

Senior Vice President of Investor Relations & Corporate Affairs————

Bryan Ridgell

Senior Vice President of Portfolio & Project Management and Chief of Staff————

Shanthakumar Tyavanagimatt

Senior Vice President & Chief Technical Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Apr 13, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

1

$19,118.70

Net Transaction Value

−$19,118.70

Net selling

Most Active

ROBERTSON MICHELLE

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Feb 18, 26

ROBERTSON MICHELLE

Direct

Sell$19.1K

Summary

Insiders reported 0 buys worth $0.00 and 1 sells worth $19,118.70 over the last 12 months. That adds up to net selling of $19,118.70. ROBERTSON MICHELLE was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+575.7%
+31.4% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +575.7% over three years. Forward estimates point to Revenue at +31.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Geron Corporation compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about GERN's management, answered from reported figures.

Who manages GERN?

Geron Corporation (GERN) lists 10 active executives. The top listed executive is Ahmed ElNawawi, Executive Vice President & Chief Commercial Officer.

Are GERN insiders buying or selling?

Recent insider activity shows net buying of $73.46M.